MOUNJARO (AUTOINJECTOR) - (2.5 mg/0.5 mL, 5 mg/0.5 mL ; Subcutaneous Solution)

Generic Name	TIRZEPATIDE	Innovator	Eli Lilly
Dosage	2.5 mg/0.5 mL, 5 mg/0.5 mL ; Subcutaneous Solution	Branded US Sales	More Than $1000 mn
Probable FTF	More Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	Less Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	MOUNJARO® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
****** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events

MOUNJARO (AUTOINJECTOR) - (7.5 mg/0.5 mL ; Subcutaneous Solution)

Generic Name	TIRZEPATIDE	Innovator	Eli Lilly
Dosage	7.5 mg/0.5 mL ; Subcutaneous Solution	Branded US Sales	More Than $1000 mn
Probable FTF	More Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	MOUNJARO® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
****** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events

MOUNJARO (AUTOINJECTOR) - (10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL ; Subcutaneous Solution)

Generic Name	TIRZEPATIDE	Innovator	Eli Lilly
Dosage	10 mg/0.5 mL, 12.5 mg/0.5 mL, 15 mg/0.5 mL ; Subcutaneous Solution	Branded US Sales	More Than $1000 mn
Probable FTF	More Than 5	Known Para IV Filers	More Than 5
Other ANDA developers	More Than 5	Tentative Approvals	None
Final Approvals	None	Generic Launches	None
Indication	MOUNJARO® is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
Complexities	Yes

Executive Summary

Patent Status

Launch Timelines and Competition

Company	FTF Status / 180 days exclusivity	30-Months stay	Current Litigation Status	Current Approval Status	Likelihood of launch
*******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****
****** ******	*** \ *********	*** **, ****	*******	****	*** ****** *** ****

Chronology Of Events